On December 19th, Hurun Research Institute and Guangzhou Nansha jointly released the "2023 Hurun Global Cheetah Enterprise List", which lists the high growth enterprises that are most likely to reach a unicorn level valuation of one billion US dollars within five years after their establishment in 2000. This is the first time that Hurun Research Institute has released the "Global Cheetah Enterprise". As a biopharmaceutical company dedicated to the research and development of therapeutic antibody new drugs with independent intellectual property rights, Enron Venture Capital Investment Enterprise Leads Biolabs  is honored to be on the list.

The list shows that there are 747 Cheetah companies worldwide, distributed in 198 cities across 34 countries and regions. These Cheetah companies have an average establishment time of about 7 years and an average valuation of nearly 3 billion yuan. Among them, China and the United States lead with 291 and 246 respectively, accounting for 72% of the total number of known cheetah companies worldwide. From the distribution cities of Cheetah enterprises, Shanghai is the global capital of Cheetah enterprises, with 64 companies, while Nanjing, where Weili Zhibo is located, has a total of 10 companies on the list, including 5 companies from Jiangbei New Area.
 

Hurun Baifu Chairman and Chief Research Officer Hurun said, "Cheetah represents the future economy. What these companies are doing, where they are doing it, which industries they represent to attract top talents and smart capital from around the world, and which countries and cities have the best entrepreneurial ecosystem."

Leads Biolabs  is honored to be on the list, reflecting recognition of Leads Biolabs 's innovation in the field of biomedicine. Since its establishment, Leads Biolabs  has focused on unmet pharmaceutical needs and adhered to the research and development of antibody new drugs with independent intellectual property rights for the treatment of tumors and other major diseases. On the single target antibody and bispecific antibody new drug research and development technology platform, it has a rich research and development pipeline consisting of more than 20 new tumor immunity, autoimmune, and ADC treatment antibody projects. At the same time, we are also committed to creating a win-win ecosystem for collaborative innovation, reaching strategic cooperation with numerous enterprises and institutions, promoting the development of the biopharmaceutical field through open innovation, and meeting unmet clinical needs.